Is porocarcinoma of the thigh classified as a squamous cell carcinoma or as a soft‑tissue sarcoma?

Porocarcinoma is NOT a squamous cell carcinoma—it is a distinct malignant adnexal tumor arising from eccrine sweat glands

Porocarcinoma of the thigh should be classified and managed as a skin adnexal carcinoma, not as squamous cell carcinoma or soft tissue sarcoma. While it can histologically mimic squamous cell carcinoma, porocarcinoma has a fundamentally different cell of origin and biological behavior.

Key Distinguishing Features

Histologic and Immunohistochemical Differentiation

Porocarcinoma can be reliably distinguished from squamous cell carcinoma through specific immunohistochemical markers 1, 2:

• CD117 (c-KIT): Positive in 78.6-100% of porocarcinomas with moderate to strong, diffuse staining, versus only 13.6-19.4% of SCCs with focal expression limited to basal layers 1, 2
• Cytokeratin 19: Strongly positive in >20% of tumor cells in 92.9% of porocarcinomas, versus only 40.9% of SCCs (mostly with ≤10% focal expression) 1
• BerEP4: Positive in 57.1% of porocarcinomas versus only 9.1% of SCCs 1
• CEA: Highlights ductal lumina in 100% of porocarcinomas, a key architectural feature absent in SCC 2
• NUTM1: Highly specific (though not sensitive) for porocarcinoma—expressed in 28.6% of porocarcinomas but not in SCCs 1

Why This Distinction Matters Clinically

The classification directly impacts treatment approach and prognosis:

Porocarcinoma behavior differs from SCC:

• Higher propensity for lymph node metastases (up to 20% of cases)
• Different metastatic patterns and prognosis
• Requires sentinel lymph node evaluation in many cases
• Does not respond to SCC-specific systemic therapies (cemiplimab, pembrolizumab)

Porocarcinoma is NOT a soft tissue sarcoma:

• Arises from epithelial structures (eccrine ducts), not mesenchymal tissue
• Does not follow soft tissue sarcoma staging or treatment algorithms 3
• The ESMO soft tissue sarcoma guidelines 3 do not apply to epithelial skin malignancies

Management Approach

Primary treatment is wide local excision with clear margins, similar to other high-risk skin cancers but distinct from both SCC and sarcoma protocols:

• Surgical margins should be 1-2 cm when anatomically feasible
• Sentinel lymph node biopsy should be strongly considered given the high rate of nodal metastases
• Adjuvant radiation therapy may be considered for high-risk features (positive margins, perineural invasion, nodal involvement)

Common Diagnostic Pitfall

The most critical error is misdiagnosing porocarcinoma as poorly differentiated SCC based on routine H&E morphology alone. When encountering a poorly differentiated carcinoma in the skin, particularly with ductal differentiation or clear cell features, always request CD117, cytokeratin 19, and CEA immunostains to exclude porocarcinoma 1, 2. This prevents inappropriate treatment with SCC protocols and ensures proper staging evaluation including nodal assessment.

The sarcomatoid variant of SCC 4 can further complicate diagnosis, but even these maintain epithelial marker positivity (p40, p63, high-molecular-weight cytokeratins) without the ductal architecture and CD117 expression pattern characteristic of porocarcinoma.